Valeo Financial Advisors LLC Buys New Stake in Alexion Pharmaceuticals, Inc. (ALXN)
Valeo Financial Advisors LLC bought a new stake in shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund bought 1,045 shares of the biopharmaceutical company’s stock, valued at approximately $147,000.
Several other institutional investors also recently added to or reduced their stakes in ALXN. Fiduciary Trust Co. bought a new stake in Alexion Pharmaceuticals during the 2nd quarter valued at $111,000. Penserra Capital Management LLC increased its stake in Alexion Pharmaceuticals by 13.0% during the 2nd quarter. Penserra Capital Management LLC now owns 1,248 shares of the biopharmaceutical company’s stock valued at $151,000 after purchasing an additional 144 shares in the last quarter. Dupont Capital Management Corp bought a new stake in Alexion Pharmaceuticals during the 3rd quarter valued at $156,000. Acadian Asset Management LLC bought a new stake in Alexion Pharmaceuticals during the 2nd quarter valued at $160,000. Finally, BT Investment Management Ltd bought a new stake in Alexion Pharmaceuticals during the 3rd quarter valued at $165,000. Institutional investors own 94.33% of the company’s stock.
ALXN has been the subject of a number of recent research reports. Zacks Investment Research upgraded shares of Alexion Pharmaceuticals from a “hold” rating to a “buy” rating and set a $144.00 price target for the company in a research note on Tuesday, October 31st. J P Morgan Chase & Co upgraded shares of Alexion Pharmaceuticals from a “neutral” rating to an “overweight” rating and boosted their price target for the company from $163.00 to $175.00 in a research note on Tuesday, September 5th. Leerink Swann restated an “outperform” rating and set a $182.00 price target (up previously from $170.00) on shares of Alexion Pharmaceuticals in a research note on Wednesday, September 13th. They noted that the move was a valuation call. Credit Suisse Group restated a “buy” rating and set a $166.00 price target on shares of Alexion Pharmaceuticals in a research note on Tuesday. Finally, Stifel Nicolaus decreased their price target on shares of Alexion Pharmaceuticals from $165.00 to $159.00 and set a “buy” rating for the company in a research note on Tuesday, October 24th. Four research analysts have rated the stock with a hold rating, eighteen have issued a buy rating and two have issued a strong buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $155.47.
Alexion Pharmaceuticals (NASDAQ:ALXN) last released its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $1.44 EPS for the quarter, topping the consensus estimate of $1.32 by $0.12. Alexion Pharmaceuticals had a return on equity of 12.55% and a net margin of 14.57%. The company had revenue of $859.00 million during the quarter, compared to the consensus estimate of $864.34 million. During the same period last year, the company earned $1.23 EPS. Alexion Pharmaceuticals’s revenue for the quarter was up 7.5% on a year-over-year basis. analysts predict that Alexion Pharmaceuticals, Inc. will post 4.82 earnings per share for the current fiscal year.
TRADEMARK VIOLATION NOTICE: “Valeo Financial Advisors LLC Buys New Stake in Alexion Pharmaceuticals, Inc. (ALXN)” was first reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this report on another website, it was copied illegally and reposted in violation of US & international trademark & copyright laws. The correct version of this report can be read at https://www.thecerbatgem.com/2017/12/14/valeo-financial-advisors-llc-buys-new-stake-in-alexion-pharmaceuticals-inc-alxn.html.
Alexion Pharmaceuticals Company Profile
Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).
Want to see what other hedge funds are holding ALXN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN).
Receive News & Stock Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related stocks with our FREE daily email newsletter.